Literature DB >> 18468680

Semenogelin I expression in myeloma cells can be upregulated pharmacologically.

Yana Zhang1, Zhiqing Wang, Jian Zhang, Benjamin Farmer, Seah H Lim.   

Abstract

Semenogelin (SEMG) I is a Cancer-Testis (CT) antigen that we have found to be expressed in myeloma cells. In this study, we set out to determine whether the expression of SEMG I could be upregulated pharmacologically. We found that SEMG I expression in myeloma cells can be upregulated by 5-azacytidine, IL-4 and IL-6. The mechanisms of SEMG I gene upregulation by 5-azacytidine is unclear since there was no correlation between the methylation of the single CpG dinucleotide at position -11 and SEMG I expression. Both IL-4 and IL-6 appeared to enhance SEMG I expression through increasing its promoter function.

Entities:  

Mesh：

Substances：

Year:  2008        PMID： 18468680      PMCID： PMC2615790          DOI： 10.1016/j.leukres.2008.03.036

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  17 in total

1.  Semenogelins are ectopically expressed in small cell lung carcinoma.

Authors:  R G Rodrigues; A Panizo-Santos; J A Cashel; H C Krutzsch; M J Merino; D D Roberts
Journal:  Clin Cancer Res       Date:  2001-04       Impact factor: 12.531

2.  Gene structure of semenogelin I and II. The predominant proteins in human semen are encoded by two homologous genes on chromosome 20.

Authors:  M Ulvsbäck; C Lazure; H Lilja; N K Spurr; V V Rao; C Löffler; I Hansmann; A Lundwall
Journal:  J Biol Chem       Date:  1992-09-05       Impact factor: 5.157

3.  Semenogelin, the predominant protein in human semen. Primary structure and identification of closely related proteins in the male accessory sex glands and on the spermatozoa.

Authors:  H Lilja; P A Abrahamsson; A Lundwall
Journal:  J Biol Chem       Date:  1989-01-25       Impact factor: 5.157

Review 4.  DNA methylation changes and multiple myeloma.

Authors:  M H Ng; I H Wong; K W Lo
Journal:  Leuk Lymphoma       Date:  1999-08

5.  Pattern of gene expression and immune responses to Semenogelin 1 in chronic hematologic malignancies.

Authors:  Yana Zhang; Zhiqing Wang; Haichao Liu; Francis J Giles; Seah H Lim
Journal:  J Immunother       Date:  2003 Nov-Dec       Impact factor: 4.456

6.  Semenogelin I and II, the predominant human seminal plasma proteins, are also expressed in non-genital tissues.

Authors:  Ake Lundwall; Anders Bjartell; A Yvonne Olsson; Johan Malm
Journal:  Mol Hum Reprod       Date:  2002-09       Impact factor: 4.025

Review 7.  CpG island hypermethylation and tumor suppressor genes: a booming present, a brighter future.

Authors:  Manel Esteller
Journal:  Oncogene       Date:  2002-08-12       Impact factor: 9.867

Review 8.  Epigenetics in human disease and prospects for epigenetic therapy.

Authors:  Gerda Egger; Gangning Liang; Ana Aparicio; Peter A Jones
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

9.  Cancer testis antigens expression in mesothelioma: role of DNA methylation and bioimmunotherapeutic implications.

Authors:  L Sigalotti; S Coral; M Altomonte; L Natali; G Gaudino; P Cacciotti; R Libener; F Colizzi; G Vianale; F Martini; M Tognon; A Jungbluth; J Cebon; E Maraskovsky; L Mutti; M Maio
Journal:  Br J Cancer       Date:  2002-03-18       Impact factor: 7.640

10.  Sp17 gene expression in myeloma cells is regulated by promoter methylation.

Authors:  Z Wang; Y Zhang; B Ramsahoye; D Bowen; S H Lim
Journal:  Br J Cancer       Date:  2004-10-18       Impact factor: 7.640
View more
  6 in total

1.  Body fluid identification by mass spectrometry.

Authors:  Heyi Yang; Bo Zhou; Haiteng Deng; Mechthild Prinz; Donald Siegel
Journal:  Int J Legal Med       Date:  2013-03-24       Impact factor: 2.686

2.  Cancer-testis antigens: the current status on antigen regulation and potential clinical use.

Authors:  Seah H Lim; Yana Zhang; Jian Zhang
Journal:  Am J Blood Res       Date:  2012-01-01

3.  Core promoter sequence of SEMG I spans between the two putative GATA-1 binding domains and is responsive to IL-4 and IL-6 in myeloma cells.

Authors:  Yana Zhang; Zhiqing Wang; Jian Zhang; Seah H Lim
Journal:  Leuk Res       Date:  2008-07-07       Impact factor: 3.156

Review 4.  Emerging roles of cancer-testis antigenes, semenogelin 1 and 2, in neoplastic cells.

Authors:  Oleg Shuvalov; Alyona Kizenko; Alexey Petukhov; Olga Fedorova; Alexandra Daks; Nikolai Barlev
Journal:  Cell Death Discov       Date:  2021-05-08

5.  Azacytidine induces necrosis of multiple myeloma cells through oxidative stress.

Authors:  Enbing Tian; Haiping Tang; Renhua Xu; Chongdong Liu; Haiteng Deng; Qingtao Wang
Journal:  Proteome Sci       Date:  2013-06-13       Impact factor: 2.480

6.  Identification of Urinary Biomarkers for Exercise-Induced Immunosuppression by iTRAQ Proteomics.

Authors:  Guoqin Xu; Wentao Lin; Andrew J McAinch; Xu Yan; Xiquan Weng
Journal:  Biomed Res Int       Date:  2020-01-23       Impact factor: 3.411
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.